Inhibition of AKT promotes FOXO3a-dependent apoptosis in prostate cancer

Cell Death and Disease

Volumn 7, Issue 2, 2016, Pages

  Das, T P ^a   Suman, S ^a   Alatassi, H ^a   Ankem, M K ^a   Damodaran, C ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; FOXO3 PROTEIN, HUMAN; PROSTATE APOPTOSIS RESPONSE-4 PROTEIN; PROTEIN KINASE B; TRANSCRIPTION FACTOR FKHRL1; WITHAFERIN A; WITHANOLIDE;

ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BAGG ALBINO MOUSE; BINDING SITE; CELL SURVIVAL; DEFICIENCY; DRUG EFFECTS; GENETICS; HUMAN; MALE; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; PROMOTER REGION; PROSTATE TUMOR; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BINDING SITES; CELL LINE, TUMOR; CELL SURVIVAL; FORKHEAD BOX PROTEIN O3; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ANDROGEN; RNA INTERFERENCE; SIGNAL TRANSDUCTION; WITHANOLIDES;

EID: 84986322682     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2015.403     Document Type: Article

References (51)

1. Testa JR, Bellacosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 2001;98:10983-10985.
2. Xiao GH, Jeffers M, Bellacosa A, Mitsuuchi Y, Vande Woude GF, Testa JR. Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc Natl Acad Sci USA 2001;98:247-252.
3. Arboleda MJ, Lyons JF, Kabbinavar FF, Bray MR, Snow BE, Ayala R et al. Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res 2003;63:196-206.
4. Lee MW, Kim DS, Lee JH, Lee BS, Lee SH, Jung HL et al. Roles of AKT1 and AKT2 in nonsmall cell lung cancer cell survival, growth, and migration. Cancer Sci 2011;102:1822-1828.
5. Virtakoivu R, Pellinen T, Rantala JK, Perala M, Ivaska J. Distinct roles of AKT isoforms in regulating beta1-integrin activity, migration, and invasion in prostate cancer. Mol Biol Cell 2012;23:3357-3369.
6. Brunet A, Datta SR, Greenberg ME. Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr Opin Neurobiol 2001;11:297-305.
7. Yang JY, Hung MC. A new fork for clinical application: targeting forkhead transcription factors in cancer. Clin Cancer Res 2009;15:752-757.
8. Guo JP, Tian W, Shu S, Xin Y, Shou C, Cheng JQ. IKBKE phosphorylation and inhibition of FOXO3a: a mechanism of IKBKE oncogenic function. PLoS ONE 2013;8:e63636.
9. Guo S, Sonenshein GE. Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway. Mol Cell Biol 2004;24:8681-8690.
10. Habashy HO, Rakha EA, Aleskandarany M, Ahmed MA, Green AR, Ellis IO et al. FOXO3a nuclear localisation is associated with good prognosis in luminal-like breast cancer. Breast Cancer Res Treat 2011;129:11-21.
11. Yang L, Xie S, Jamaluddin MS, Altuwaijri S, Ni J, Kim E et al. Induction of androgen receptor expression by phosphatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells. J Biol Chem 2005;280:33558-33565.
12. Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, Garcia-Echeverria C et al. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci USA 2009;106:268-273.
13. Yu C, Zhang Z, Liao W, Zhao X, Liu L, Wu Y et al. The tumor-suppressor gene Nkx2.8 suppresses bladder cancer proliferation through upregulation of FOXO3a and inhibition of the MEK/ERK signaling pathway. Carcinogenesis 2012;33:678-686.
14. Lu M, Xiang J, Xu F, Wang Y, Yin Y, Chen D. The expression and significance of pThr32-FOXO3a in human ovarian cancer. Med Oncol 2012;29:1258-1264.
15. Burgering BM, Medema RH. Decisions on life and death: FOXO Forkhead transcription factors are in command when PKB/Akt is off duty. J Leukocyte Biol 2003;73:689-701.
16. Sanphui P, Biswas SC. FoxO3a is activated and executes neuron death via Bim in response to beta-amyloid. Cell Death Dis 2013;4:e625.
17. Huang H, Tindall DJ. Dynamic FoxO transcription factors. J Cell Sci 2007;120:2479-2487.
18. Huang H, Regan KM, Wang F, Wang D, Smith DI, van Deursen JM et al. Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc Natl Acad Sci USA 2005;102:1649-1654.
19. de Thonel A, Hazoume A, Kochin V, Isoniemi K, Jego G, Fourmaux E et al. Regulation of the proapoptotic functions of prostate apoptosis response-4 (Par-4) by casein kinase 2 in prostate cancer cells. Cell Death Dis 2014;5:e1016.
20. Johnstone RW, See RH, Sells SF, Wang J, Muthukkumar S, Englert C et al. A novel repressor, par-4, modulates transcription and growth suppression functions of the Wilms' tumor suppressor WT1. Mol Cell Biol 1996;16:6945-6956.
21. Burikhanov R, Zhao Y, Goswami A, Qiu S, Schwarze SR, Rangnekar VM. The tumor suppressor Par-4 activates an extrinsic pathway for apoptosis. Cell 2009;138:377-388.
22. Joshi J, Fernandez-Marcos PJ, Galvez A, Amanchy R, Linares JF, Duran et al. Par-4 inhibits Akt and suppresses Ras-induced lung tumorigenesis. EMBO J 2008;27:2181-2193.
23. Garcia-Cao I, Duran A, Collado M, Carrascosa MJ, Martin-Caballero J, Flores JM et al. Tumour-suppression activity of the proapoptotic regulator Par4. EMBO Rep 2005;6:577-583.
24. Burikhanov R, Shrestha-Bhattarai T, Hebbar N, Qiu S, Zhao Y, Zambetti GP et al. Paracrine apoptotic effect of p53 mediated by tumor suppressor Par-4. Cell Rep 2014;6:271-277.
25. Gurumurthy S, Goswami A, Vasudevan KM, Rangnekar VM. Phosphorylation of Par-4 by protein kinase A is critical for apoptosis. Mol Cell Biol 2005;25:1146-1161.
26. Azmi AS, Philip PA, Zafar SF, Sarkar FH, Mohammad RM. PAR-4 as a possible new target for pancreatic cancer therapy. Expert Opin Ther Targets 2010;14:611-620.
27. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics. CA Cancer J Clin 2003;53:5-26.
28. Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A et al. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer 1999;81:242-251.
29. Lee TJ, Lee JT, Kim SH, Choi YH, Song KS, Park JW et al. Overexpression of Par-4 enhances thapsigargin-induced apoptosis via down-regulation of XIAP and inactivation of Akt in human renal cancer cells. J Cell Biochem 2008;103:358-368.
30. Franchitto A, Torrice A, Semeraro R, Napoli C, Nuzzo G, Giuliante F et al. Prostate apoptosis response-4 is expressed in normal cholangiocytes, is down-regulated in human cholangiocarcinoma, and promotes apoptosis of neoplastic cholangiocytes when induced pharmacologically. Am J Pathol 2010;177:1779-1790.
31. Rah B, Amin H, Yousuf K, Khan S, Jamwal G, Mukherjee D et al. A novel MMP-2 inhibitor 3-azidowithaferin A (3-azidoWA) abrogates cancer cell invasion and angiogenesis by modulating extracellular Par-4. PLoS ONE 2012;7:e44039.
32. Srinivasan S, Ranga RS, Burikhanov R, Han SS, Chendil D. Par-4-dependent apoptosis by the dietary compound withaferin A in prostate cancer cells. Cancer Res 2007;67:246-253.
33. van Weeren PC, de Bruyn KM, de Vries-Smits AM, van Lint J, Burgering BM. Essential role for protein kinase B (PKB) in insulin-induced glycogen synthase kinase 3 inactivation. Characterization of dominant-negative mutant of PKB. J Biol Chem 1998;273:13150-13156.
34. Goc A, Al-Husein B, Katsanevas K, Steinbach A, Lou U, Sabbineni H et al. Targeting Srcmediated Tyr216 phosphorylation and activation of GSK-3 in prostate cancer cells inhibit prostate cancer progression in vitro and in vivo. Oncotarget 2014;5:775-787.
35. Jarvius M, Paulsson J, Weibrecht I, Leuchowius KJ, Andersson AC, Wahlby C et al. In situ detection of phosphorylated platelet-derived growth factor receptor beta using a generalized proximity ligation method. Mol Cell Proteomics 2007;6:1500-1509.
36. Grille SJ, Bellacosa A, Upson J, Klein-Szanto AJ, van Roy F, Lee-Kwon W et al. The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res 2003;63:2172-2178.
37. Sipos F, Galamb O. Epithelial-to-mesenchymal and mesenchymal-to-epithelial transitions in the colon. World J Gastroenterol 2012;18:601-608.
38. Goswami A, Burikhanov R, de Thonel A, Fujita N, Goswami M, Zhao Y et al. Binding and phosphorylation of par-4 by akt is essential for cancer cell survival. Mol Cell 2005;20:33-44.
39. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999;96:857-868.
40. Arden KC. FoxO: linking new signaling pathways. Mol Cell 2004;14:416-418.
41. Tran H, Brunet A, Grenier JM, Datta SR, Fornace AJ Jr., DiStefano PS et al. DNA repair pathway stimulated by the forkhead transcription factor FOXO3a through the Gadd45 protein. Science (New York, NY) 2002;296:530-534.
42. Lynch RL, Konicek BW, McNulty AM, Hanna KR, Lewis JE, Neubauer BL et al. The progression of LNCaP human prostate cancer cells to androgen independence involves decreased FOXO3a expression and reduced p27KIP1 promoter transactivation. Mol Cancer Res 2005;3:163-169.
43. Skurk C, Maatz H, Kim HS, Yang J, Abid MR, Aird WC et al. The Akt-regulated forkhead transcription factor FOXO3a controls endothelial cell viability through modulation of the caspase-8 inhibitor FLIP. J Biol Chem 2004;279:1513-1525.
44. Kornblau SM, Singh N, Qiu Y, Chen W, Zhang N, Coombes KR. Highly phosphorylated FOXO3A is an adverse prognostic factor in acute myeloid leukemia. Clin Cancer Res 2010;16:1865-1874.
45. Stan SD, Hahm ER, Warin R, Singh SV. Withaferin A causes FOXO3a- and Bim-dependent apoptosis and inhibits growth of human breast cancer cells in vivo. Cancer Res 2008;68:7661-7669.
46. Sunters A, Fernandez de Mattos S, Stahl M, Brosens JJ, Zoumpoulidou G, Saunders CA et al. FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J Biol Chem 2003;278:49795-49805.
47. Suman S, Kurisetty V, Das TP, Vadodkar A, Ramos G, Lakshmanaswamy R et al. Activation of AKT signaling promotes epithelial-mesenchymal transition and tumor growth in colorectal cancer cells. Mol Carcinog 2014;53:E151-E160.
48. Das TP, Suman S, Damodaran C. Induction of reactive oxygen species generation inhibits epithelial-mesenchymal transition and promotes growth arrest in prostate cancer cells. Mol Carcinog 2014;53:537-547.
49. Suman S, Das TP, Reddy R, Nyakeriga AM, Luevano JE, Konwar D et al. The pro-apoptotic role of autophagy in breast cancer. Br J Cancer 2014;111:309-317.
50. Blokzijl A, Nong R, Darmanis S, Hertz E, Landegren U, Kamali-Moghaddam M. Protein biomarker validation via proximity ligation assays. Biochim Biophys Acta 2014;1844:933-939.
51. Weibrecht I, Leuchowius KJ, Clausson CM, Conze T, Jarvius M, Howell WM et al. Proximity ligation assays: a recent addition to the proteomics toolbox. Expert Rev Proteomics 2010;7:401-409.